IBRX is trading 136.6% above its estimated fair value, a level that flags significant overvaluation risk.
IBRX fair value assessment
IBRX is trading 136.6% above its estimated fair value, a level that flags significant overvaluation risk.
Reality vs. Belief
IBRX's price is driven mostly by belief and is detached from its underlying fundamentals.
IBRX signal snapshot
IBRX projected price & trade signal
What's driving IBRX's price
The story driving IBRX right now: ImmunityBio (IBRX) reported Q2 earnings and sales that surpassed analyst estimates, driven by robust uptake of its product Anktiva, suggesting strong operational performance. High volatility-momentum readings (100) indicate significant narrative-driven price displacement.
Market Prism's verdict on IBRX
Market Prism flags IBRX as Narrative Risk — the supporting story has structural weak points that raise the odds of a sharp repricing. Narrative energy is moderating at 50%, an early sign of fatigue.
Valuation outlook for IBRX
Elevated narrative risk means the move is fragile. Watch for the first crack in the story — these names tend to reprice faster than the fundamentals change. The 136.6% fair-value deviation is extreme and, historically, tends to revert within 30–60 trading days.
Frequently asked questions
Is IBRX overvalued right now?
IBRX is trading 136.6% above its estimated fair value, a level that flags significant overvaluation risk.
What is Market Prism's verdict on IBRX?
Market Prism flags IBRX as Narrative Risk — the supporting story has structural weak points that raise the odds of a sharp repricing. Narrative energy is moderating at 50%, an early sign of fatigue.
What happens next for IBRX?
Elevated narrative risk means the move is fragile. Watch for the first crack in the story — these names tend to reprice faster than the fundamentals change. The 136.6% fair-value deviation is extreme and, historically, tends to revert within 30–60 trading days.
Is IBRX a good value investment?
Market Prism does not provide investment recommendations. Our forensic analysis shows: IBRX is carrying elevated narrative risk, trading 136.6% above estimated fair value.